Eupraxia Pharmaceuticals Statistics
Total Valuation
EPRX has a market cap or net worth of $140.82 million. The enterprise value is $143.69 million.
Important Dates
The last earnings date was Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EPRX has 35.85 million shares outstanding. The number of shares has increased by 37.52% in one year.
| Current Share Class | 35.85M |
| Shares Outstanding | 35.85M |
| Shares Change (YoY) | +37.52% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 24.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.21 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.00, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.00 |
| Quick Ratio | 12.59 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -43.00 |
Financial Efficiency
Return on equity (ROE) is -116.77% and return on invested capital (ROIC) is -62.63%.
| Return on Equity (ROE) | -116.77% |
| Return on Assets (ROA) | -52.06% |
| Return on Invested Capital (ROIC) | -62.63% |
| Return on Capital Employed (ROCE) | -101.48% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$826,308 |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -402 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +45.39% in the last 52 weeks. The beta is 1.52, so EPRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.52 |
| 52-Week Price Change | +45.39% |
| 50-Day Moving Average | 3.63 |
| 200-Day Moving Average | 3.20 |
| Relative Strength Index (RSI) | 56.66 |
| Average Volume (20 Days) | 17,901 |
Short Selling Information
The latest short interest is 139,261, so 0.39% of the outstanding shares have been sold short.
| Short Interest | 139,261 |
| Short Previous Month | 142,973 |
| Short % of Shares Out | 0.39% |
| Short % of Float | 0.56% |
| Short Ratio (days to cover) | 10.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -27.43M |
| Pretax Income | -23.08M |
| Net Income | -27.27M |
| EBITDA | -27.32M |
| EBIT | -27.43M |
| Earnings Per Share (EPS) | -$0.76 |
Full Income StatementBalance Sheet
The company has $27.45 million in cash and $52,774 in debt, giving a net cash position of $27.40 million or $0.76 per share.
| Cash & Cash Equivalents | 27.45M |
| Total Debt | 52,774 |
| Net Cash | 27.40M |
| Net Cash Per Share | $0.76 |
| Equity (Book Value) | 27.03M |
| Book Value Per Share | -0.09 |
| Working Capital | 26.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$29.86 million and capital expenditures -$266,482, giving a free cash flow of -$30.13 million.
| Operating Cash Flow | -29.86M |
| Capital Expenditures | -266,482 |
| Free Cash Flow | -30.13M |
| FCF Per Share | -$0.84 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |